Skip to content

Effect of omega-3 versus placebo on the clinical and paraclinical situation in patients with refractory epilepsy

Effect of omega-3 versus placebo on the clinical and paraclinical situation in patients with refractory epilepsy: a triple blind randomized clinical trial

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT201604179014N96
Enrollment
50
Registered
2016-04-26
Start date
2015-09-11
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Refractory epilepsy. Epilepsy

Interventions

Intervention 1: Routine treatment plus oral omega-3 one tablet 1000 mg twice a day for 4 months. Intervention 2: Routine treatment plus a placebo tablet twice a day for 4 months.
Treatment - Drugs
Placebo
Routine treatment plus oral omega-3 one tablet 1000 mg twice a day for 4 months
Routine treatment plus a placebo tablet twice a day for 4 months

Sponsors

Vice-chancellor for Research the Technology, Hamadan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 55 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: (a) age of 18 to 55 years; (b) having refractory epilepsy. Exclusion criteria: (a) pregnancy or breastfeeding; (b) having underling diseases such as lever disease, kidney disease, active infection, pulmonary disease, hypertension, dementia, and mental retardation; (c) catamenial epilepsy.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Assessing the frequency of seizures. Timepoint: before treatment and every month for 4 months. Method of measurement: by taking history.

Secondary

MeasureTime frame
Assessing serum level of interleukin-6. Timepoint: before treatment and 4 months later. Method of measurement: by laboratory test.;Assessing serum level of TNF-a. Timepoint: before treatment and 4 months later. Method of measurement: by laboratory test.;Assessing electroencephalogram changes. Timepoint: before treatment and 4 months later. Method of measurement: by taking electroencephalogram.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Shaghayegh Omrani

Farshchian Hospital

drshaghayeghomrani@yahoo.com+98 81 3827 4184

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026